Xarelto Settlement: Bayer and Johnson & Johnson Settle Xarelto Lawsuits for $775 Million

On March 25, 2019, Johnson & Johnson and Bayer agreed to settle about 25,000 Xarelto lawsuits for $775 million. The plaintiffs claim the companies failed to warn about the potentially fatal bleeding that can occur when taking the drug. The Xarelto settlement will be split evenly between the two companies.

What Are the Details Behind the Settlement?

Bayer AG and Johnson & Johnson jointly developed Xarelto as a first line of defense against strokes and blood clots. However, unlike its competitor, Warfarin, where Vitamin K can be administered if a person begins bleeding internally, Xarelto, does not have an antidote for bleeding.

The Plaintiffs argued that the recommended dosage of Xarelto caused an unreasonable risk of bleeding. They also claimed the defendants failed to test a lower dose to see if it had a more favorable risk-benefit profile for prevention of venous thromboembolism. The defendants claimed the drug was life-saving and the FDA approved it.

There were a number of bellwether trials. The defendants won all of but one of them and ultimately were able to have the one plaintiff’s verdict overturned. Unfortunately, none of the trials resulted in a plaintiff being able to keep a verdict.

The deal ends claims in multidistrict litigation consolidated in Louisiana, as well as claims in state courts, including 2000 claims in Philadelphia. The settlement also resolves new claims filed by patients who retained a lawyer by March 11 and will file a suit by April 4, according to a statement from the plaintiffs’ attorneys.

The drug brought in $2.5 billion in revenues in 2018, placing it among the top-selling pharmaceutical products. Nearly 45 million patients have been prescribed Xarelto worldwide.

What Now?

Unfortunately, GoldenbergLaw can no longer accept new Xarelto claims. Existing clients will be hearing from their litigation team shortly with details on the next steps of the settlement. It is our hope that the Xarelto Settlement will help the plaintiffs move forward in their recovery and put this difficult chapter behind them. If you have any questions about Xarelto or the Xarelto settlement, please contact your legal assistant or attorney.


On February 14, 2019, both class action and personal injury cases involving contaminated valsartan-containing drugs were consolidated into a multi-district litigation (MDL) in the District of New Jersey before the Honorable Robert B. Kugler.

Valsartan is a medication prescribed to treat high blood pressure and related conditions.  Recent investigations by the FDA revealed that pills distributed by at least four Active Pharmaceutical Ingredient (API) manufacturers were contaminated with carcinogenic substances, called NDMA and NDEA.  As a result, both the US FDA and the European Medicines Agency (among other foreign regulatory agencies) predicted that some consumers who took these contaminated pills for a number of years will get cancer.

This MDL will be comprised of both personal injury cases, as well as class actions. As of the time the Judicial Panel on Multidistrict Litigation (JPML) issued its order creating the MDL, there were approximately 40 cases filed.  The MDL includes all manufacturers of the recalled valsartan. For a list of these manufacturers, visit the FDA’s website.

The JPML determined that New Jersey was an appropriate venue for the litigation, primarily because many defendants have headquarters in New Jersey, and it is likely that both relevant documents and witnesses will be located in New Jersey as well.  Further, Judge Kugler previously presided over a litigation involving a different ARB drug, olmesartan (Benicar).

There is currently no decision on whether other angiotensin II receptor blockers (ARBs), such as irbesartan and losartan, will be included in this MDL.

GoldenbergLaw is currently accepting valsartan, losartan, and irbesartan cases.  To learn more about this litigation, please visit our valsartan page. You can also find out whether your medication has been recalled by visiting the FDA’s website.  If you or a loved one took one of these drugs and contracted liver, colorectal, stomach, intestinal, and kidney cancer, please contact us. We deliver the gold standard advocacy you deserve.

Partner Laura Pittner Appointed to PSC in Zimmer M/L Taper Hip MDL

GoldenbergLaw Partner Laura Pittner has been appointed to the Plaintiffs’ Steering Committee (PSC) in the Zimmer M/L Taper hip Multidistrict Litigation (MDL). This occurred on December 14, 2018, by the Hon. Jesse M. Furman, United States District Judge for the Southern District of New York.

About Laura PittnerPartner Laura Pittner

Laura has extensive experience in hip device litigations and has led GoldenbergLaw’s defective hip practice in the Depuy ASR, Depuy Pinnacle, Biomet M2A, Wright Profemur, Conserve and Dynasty Hip Systems, Zimmer Durom Cup, Smith & Nephew Birmingham Hip, Stryker Rejuvenate, and Stryker LFIT V40 cases. Her leadership has resulted in millions of dollars of settlements recovered for our clients.

Laura has also helped in the leadership of several other mass torts litigations, including in Benicar, a heart pressure medication alleged to cause gastrointestinal injuries, and Farxiga, a diabetes drug alleged to cause serious diabetic ketoacidosis.

Laura has been with GoldenbergLaw since 2010. She is a knowledgeable leader in mass tort and product liability cases. In addition, her practice includes motor vehicle, chemical exposure, and premises liability cases. She is also the proud mother of twin boys Cecil and Odin.

Zimmer M/L Taper Hip Prosthesis and Versys Femoral Heads

The Zimmer M/L Taper and Kinectiv hip systems are comprised of the femoral components of an artificial hip device. The devices are designed to be made of up two pieces, the neck and stem, not dissimilar to the Stryker Rejuvenate hip device that was previously the subject of consolidated litigations that resulted in substantial settlements. While the Zimmer M/L devices have not yet been recalled, there have been several reports of early failure associated with corrosion and metal wear at the neck-stem interface requiring revision.

In December 2017, a verdict was secured against Zimmer, the maker of the M/L Taper device in a case tried by another law firm in New Mexico. The plaintiff in that case was awarded over $2,000,000.

Several M/L Taper cases have been filed in various state and federal courts across the country. In October 2018, the Judicial Panel of Multidistrict Litigation ordered that Zimmer M/L Taper cases throughout the United States be consolidated in the Southern District of New York before the Honorable Paul Crotty. The first case management conference occurred on December 6, 2018. At that time, the proposed Plaintiffs’ leadership committee was approved.

Contact Us

GoldenbergLaw is currently investigating Zimmer M/L Taper cases and other defective hip replacement cases. If you or a loved one has been fitted with a defective hip replacement, contact GoldenbergLaw.